| Date | Title | Description |
| 02.08.2024 | Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 | Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended ... |
| 17.06.2024 | Vaxart Provides Business Update | — Cash runway extended into 2026 —
— Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million —
— Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noro... |
| 13.06.2024 | Vaxart Announces $40 Million Underwritten Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a prem... |
| 13.06.2024 | Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | — 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator —
— Vaxart anticipates initiating enrollment as early as summer 2024 —
SOUTH SAN FRANCISCO, Calif.... |
| 13.06.2024 | Vaxart Announces $40 Million Underwritten Offering of Common Stock | SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a prem... |
| 25.05.2024 | Efforts to draft pandemic treaty falter as countries disagree on steps | - |
| 07.05.2024 | Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 | Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended Ma... |
| 07.03.2024 | Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 | - |
| 06.03.2024 | Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director | - |
| 19.01.2024 | Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | - 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator -
- Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Ser... |
| 19.01.2024 | Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate | - |
| 21.06.2023 | Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET | /EIN News/ -- SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet done so. The Company urges a y... |
| 07.06.2023 | Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock | - |
| 06.06.2023 | Vaxart, Inc. Announces Proposed Public Offering of Common Stock | /EIN News/ -- SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition, Vaxart expects to grant to the ... |
| 04.05.2023 | Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results | /EIN News/ -- On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023
Continue to anticipate cash runway into Q2 2024
Conference call today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., May 04,... |
| 22.11.2022 | Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29 | /EIN News/ -- SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congr... |
| 20.10.2022 | Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8 | Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended S... |
| 10.10.2022 | Vaxart to Present at World Vaccine Congress Europe 2022 on October 13 | SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate present... |
| 07.09.2022 | Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference | SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cum... |
| 01.09.2022 | Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate | — Study met primary safety and secondary immunogenicity endpoints —
— Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects —
— Elicited cross-reactive mucosal responses in approximately 50% of subjects... |
| 31.08.2022 | Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer | Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- ... |
| 31.08.2022 | Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct befor... |
| 25.08.2022 | Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors | SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022.
"Elaine has tremendous... |
| 05.08.2022 | Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4 | All six proposals approved in the 2022 Proxy Statement
Vote strengthens the Company as it progresses its oral vaccine programs
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced today that a... |
| 28.07.2022 | Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8 | SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after the market close on M... |
| 27.07.2022 | Vaxart fournit une nouvelle mise à jour sur les votes par procuration et exhorte tous les actionnaires inscrits au 11 avril 2022 à voter avant le 3 août 2022 à 23h59 (heure de l'Est) | La proposition clé n° 2 a besoin de 0,9 % des voix conférées par des actions en circulation pour être approuvée
Les cabinets indépendants de conseil en procuration de premier plan ISS et Glass Lewis soutiennent la Proposition n° 2
SOUTH SAN... |
| 27.07.2022 | Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET | Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass
Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2
SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nas... |
| 14.07.2022 | Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022 | SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the co... |
| 01.07.2022 | Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET | Key Proposal #2 has received significant support, but additional votes are needed for approval
Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2
SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) --... |
| 30.06.2022 | Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model | Model will be used in Vaxart’s Phase II Omicron Challenge Trial
Open Orphan subsidiary hVIVO to manufacture challenge virus and conduct characterization study
SOUTH SAN FRANCISCO, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasd... |
| 16.06.2022 | Vaxart to Host Investor Q&A Webcast | Management to discuss progress on its programs, annual stockholders’ meeting proposals
Webcast to be held on June 22 at 1:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced ... |
| 02.06.2022 | Vaxart to Participate at the Jefferies Global Healthcare Conference | SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings... |
| 14.04.2022 | Vaxart to Present at World Vaccine Congress Washington 2022 on April 20 | SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.... |
| 24.02.2022 | Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates | Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19
S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary... |
| 04.01.2022 | Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference | SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings... |
| 16.12.2021 | Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron | Cross-reactivity will be assessed using samples from Phase II clinical participants and in a parallel animal challenge study
Oral tablet’s immunogenicity profile suggests it may provide cross-protection against SARS-CoV-2 variants, includin... |
| 01.12.2021 | Vaxart Announces Acquisition of Second GMP Manufacturing Facility | SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of i... |
| 23.11.2021 | Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021 | SOUTH SAN FRANCISCO, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 202... |
| 18.11.2021 | Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart | STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, Inc. (NASDAQ: VXRT), had cel... |
| 16.11.2021 | Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases | SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced today the Journal of Infectious Diseases has published complete data from Vaxart’s preclinical Hamster Challenge Study. The study shows Vax... |
| 11.11.2021 | Vaxart to Participate at Upcoming Conferences | SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and CEO, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Offi... |
| 04.11.2021 | Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results | Four clinical trials for COVID-19 and norovirus oral tablet vaccine candidates are currently ongoing
Company now operates two GMP manufacturing plants to support rapid clinical advancement of pipeline programs
Ended the quarter with $204 mi... |
| 23.08.2021 | Vaxart : Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors | SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executiv... |
| 05.08.2021 | Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results | |
| 05.08.2021 | Vaxart : Provides Business Update and Reports Second Quarter 2021 Financial Results | SOUTH SAN FRANCISCO, Calif., Aug. 5, 2021 /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) issued its business update today for the second quarter of 2021, reporting strong forward momentum in development of oral tablet vaccines that it believes... |
| 26.02.2021 | VAXART, INC.
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results | VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021
Cash and cash equivalents of $126.9 million as of December 31, 2020Conference call and webcast focused on... |
| 13.07.2020 | VAXART, INC.
Vaxart : Raises Approximately $90M in Gross Proceeds Through its At-The-Market-Facility | SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that it ha... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| 04.03.2010 | Vaxart Raises $12.5M Series B Financing | Vaxart, Inc., a San Francisco, CA-based biotechnology company developing oral-delivery vaccines, has closed a $12.5m Series B financing.
The round was led by Care Capital of Princeton NJ.
The funding will be used to advance the company’s le... |
| 15.11.2007 | Life sciences briefing: Thursday, Nov. 15, 2007 | Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma
EXPANDING ITEMS: Stay tuned.
Vaxart receives $3.3M for oral vac... |
| 15.11.2007 | Vaxart receives $3.3M for oral vaccines | See our story about this San Francisco biotech in today’s daily briefing at VenturBeat Life Sciences.
VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transformative techn... |
